AXSM
Price
$153.64
Change
-$0.55 (-0.36%)
Updated
Dec 24 closing price
Capitalization
7.75B
67 days until earnings call
Intraday BUY SELL Signals
SYRE
Price
$33.05
Change
-$0.18 (-0.54%)
Updated
Dec 24 closing price
Capitalization
2.56B
63 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

AXSM vs SYRE

Header iconAXSM vs SYRE Comparison
Open Charts AXSM vs SYREBanner chart's image
Axsome Therapeutics
Price$153.64
Change-$0.55 (-0.36%)
Volume$145.11K
Capitalization7.75B
Spyre Therapeutics
Price$33.05
Change-$0.18 (-0.54%)
Volume$291.96K
Capitalization2.56B
AXSM vs SYRE Comparison Chart in %
View a ticker or compare two or three
VS
AXSM vs. SYRE commentary
Dec 25, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AXSM is a Hold and SYRE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 25, 2025
Stock price -- (AXSM: $153.64 vs. SYRE: $33.05)
Brand notoriety: AXSM and SYRE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AXSM: 27% vs. SYRE: 37%
Market capitalization -- AXSM: $7.75B vs. SYRE: $2.56B
AXSM [@Biotechnology] is valued at $7.75B. SYRE’s [@Biotechnology] market capitalization is $2.56B. The market cap for tickers in the [@Biotechnology] industry ranges from $117.47B to $0. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AXSM’s FA Score shows that 0 FA rating(s) are green whileSYRE’s FA Score has 0 green FA rating(s).

  • AXSM’s FA Score: 0 green, 5 red.
  • SYRE’s FA Score: 0 green, 5 red.
According to our system of comparison, AXSM is a better buy in the long-term than SYRE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AXSM’s TA Score shows that 4 TA indicator(s) are bullish while SYRE’s TA Score has 2 bullish TA indicator(s).

  • AXSM’s TA Score: 4 bullish, 4 bearish.
  • SYRE’s TA Score: 2 bullish, 6 bearish.
According to our system of comparison, AXSM is a better buy in the short-term than SYRE.

Price Growth

AXSM (@Biotechnology) experienced а +3.81% price change this week, while SYRE (@Biotechnology) price change was -0.03% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.88%. For the same industry, the average monthly price growth was +4.46%, and the average quarterly price growth was +55.39%.

Reported Earning Dates

AXSM is expected to report earnings on Mar 02, 2026.

SYRE is expected to report earnings on Feb 26, 2026.

Industries' Descriptions

@Biotechnology (+2.88% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AXSM($7.75B) has a higher market cap than SYRE($2.56B). AXSM YTD gains are higher at: 81.586 vs. SYRE (41.967). AXSM (-213.94M) and SYRE (-223.64M) have comparable annual earnings (EBITDA) . SYRE has more cash in the bank: 486M vs. AXSM (325M). SYRE has less debt than AXSM: SYRE (0) vs AXSM (219M). AXSM has higher revenues than SYRE: AXSM (561M) vs SYRE (0).
AXSMSYREAXSM / SYRE
Capitalization7.75B2.56B302%
EBITDA-213.94M-223.64M96%
Gain YTD81.58641.967194%
P/E RatioN/A1.72-
Revenue561M0-
Total Cash325M486M67%
Total Debt219M0-
FUNDAMENTALS RATINGS
AXSM vs SYRE: Fundamental Ratings
AXSM
SYRE
OUTLOOK RATING
1..100
7464
VALUATION
overvalued / fair valued / undervalued
1..100
87
Overvalued
70
Overvalued
PROFIT vs RISK RATING
1..100
40100
SMR RATING
1..100
10097
PRICE GROWTH RATING
1..100
3936
P/E GROWTH RATING
1..100
10080
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SYRE's Valuation (70) in the Pharmaceuticals Major industry is in the same range as AXSM (87) in the Pharmaceuticals Other industry. This means that SYRE’s stock grew similarly to AXSM’s over the last 12 months.

AXSM's Profit vs Risk Rating (40) in the Pharmaceuticals Other industry is somewhat better than the same rating for SYRE (100) in the Pharmaceuticals Major industry. This means that AXSM’s stock grew somewhat faster than SYRE’s over the last 12 months.

SYRE's SMR Rating (97) in the Pharmaceuticals Major industry is in the same range as AXSM (100) in the Pharmaceuticals Other industry. This means that SYRE’s stock grew similarly to AXSM’s over the last 12 months.

SYRE's Price Growth Rating (36) in the Pharmaceuticals Major industry is in the same range as AXSM (39) in the Pharmaceuticals Other industry. This means that SYRE’s stock grew similarly to AXSM’s over the last 12 months.

SYRE's P/E Growth Rating (80) in the Pharmaceuticals Major industry is in the same range as AXSM (100) in the Pharmaceuticals Other industry. This means that SYRE’s stock grew similarly to AXSM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AXSMSYRE
RSI
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
74%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
84%
MACD
ODDS (%)
Bullish Trend 2 days ago
86%
Bearish Trend 2 days ago
89%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
87%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
83%
Advances
ODDS (%)
Bullish Trend 4 days ago
79%
Bullish Trend 8 days ago
85%
Declines
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
72%
Bearish Trend 2 days ago
87%
Aroon
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
84%
View a ticker or compare two or three
Interact to see
Advertisement
AXSM
Daily Signal:
Gain/Loss:
SYRE
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FREIX33.600.14
+0.42%
Franklin Equity Income R
RWMCX65.000.26
+0.40%
American Funds Washington Mutual R3
CFIMX15.960.05
+0.31%
Clipper
FLDGX14.890.04
+0.27%
Meeder Dynamic Allocation Retail
GSVPX16.980.01
+0.06%
Goldman Sachs Small/Mid Cap Equity P

AXSM and

Correlation & Price change

A.I.dvisor indicates that over the last year, AXSM has been loosely correlated with XENE. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if AXSM jumps, then XENE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AXSM
1D Price
Change %
AXSM100%
-0.36%
XENE - AXSM
39%
Loosely correlated
+1.06%
AVBP - AXSM
38%
Loosely correlated
-0.13%
SYRE - AXSM
36%
Loosely correlated
-0.54%
MIRM - AXSM
36%
Loosely correlated
+0.87%
ABEO - AXSM
36%
Loosely correlated
+2.08%
More

SYRE and

Correlation & Price change

A.I.dvisor indicates that over the last year, SYRE has been loosely correlated with BEAM. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if SYRE jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SYRE
1D Price
Change %
SYRE100%
-0.54%
BEAM - SYRE
57%
Loosely correlated
+1.33%
XNCR - SYRE
57%
Loosely correlated
-0.13%
RGNX - SYRE
57%
Loosely correlated
+0.77%
CGON - SYRE
56%
Loosely correlated
+0.22%
APGE - SYRE
56%
Loosely correlated
+1.02%
More